Noncontrast Magnetic Resonance Angiography vs Contrast-Enhanced Computed Tomography in Deep Inferior Epigastric Perforator Flap Planning: A 4-year Noninferiority Cohort Study
Aesthetic Surgery Journal · 16.09.2026 · 46 (10) · 1137-1146
DOI: 10.1093/asj/sjag140 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Aesthetic Surgery Journal, online erschienen am 07.07.2026. Verfasst von Dmitry V Melnikov und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Perforator Flap, Magnetic Resonance Angiography, Mammaplasty, Epigastric Arteries. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background
Contrast-enhanced computed tomography angiography (CTA) is considered the “gold standard” in deep inferior epigastric perforator (DIEP) planning, despite its use of iodine-based contrast and ionizing radiation exposure. In contrast, magnetic resonance angiography (MRA) provides a radiation-free alternative, but conventional MRA requires the use of an expensive and potentially harmful gadolinium-based contrast agent. The development of contrast-free MRA protocols that preserve perforator mapping accuracy represents a promising area of investigation in DIEP flap planning.
Objectives
The aim of this study was to evaluate whether an optimized noncontrast MRA protocol is noninferior to contrast-enhanced CTA in planning for delayed DIEP flap breast reconstruction (BR).
Methods
This cohort study included 131 women (mean age 45.6 ± 7.1; BMI 28.5 ± 3.9 kg/m2), who underwent delayed unilateral DIEP flap BR. Group 1 (n = 81) underwent a noncontrast MRA with tailored preprocedural preparation, positioning, and scanning. Group 2 (n = 50) underwent standard contrast-enhanced CTA.
Results
MRA significantly reduced operative time (333.0 ± 30.4 vs 348.9 ± 28.8 min; P = .003) and pedicle dissection time (35.7 ± 8.2 vs 40.1 ± 5.9 min; P < .001). The mean fascial incision length was shorter in the MRA group (9.1 ± 1.5 vs 10.6 ± 1.6 cm; P = .025). Diagnostic accuracy was 98.8% vs 99.6% (P = .4145); sensitivity was 98.3% vs 100.0%, and positive predictive value was 97.5% vs 98.7%, for MRA and CTA, respectively. The mean localization difference (ΔL) was 7.38 ± 2.59 vs 6.96 ± 2.34 mm (P = .238). Perfusion-related complication rates did not differ significantly between groups (P > .05). No significant differences were observed in baseline perforator characteristics.
Conclusions
Optimized noncontrast MRA is a clinically reliable, noninferior alternative to CTA in DIEP flap planning, with additional advantages of reduced operative and dissection times. Level of Evidence: 3 (Therapeutic) For image description, please refer to the figure legend and surrounding text.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Elina I Abdeeva, Sebastian Cotofana
Zitieren
APA
Melnikov, D. V., Abdeeva, E. I., Cotofana, S., Ivanov, S. I., Ratushniy, N. A., Vorontsov, A. V., & Gombolevskiy, V. A. (2026). Noncontrast Magnetic Resonance Angiography vs Contrast-Enhanced Computed Tomography in Deep Inferior Epigastric Perforator Flap Planning: A 4-year Noninferiority Cohort Study. Aesthetic Surgery Journal, 46(10), 1137-1146. https://doi.org/10.1093/asj/sjag140
Vancouver
Melnikov DV, Abdeeva EI, Cotofana S, Ivanov SI, Ratushniy NA, Vorontsov AV, et al. Noncontrast Magnetic Resonance Angiography vs Contrast-Enhanced Computed Tomography in Deep Inferior Epigastric Perforator Flap Planning: A 4-year Noninferiority Cohort Study. Aesthetic Surgery Journal. 2026;46(10):1137-1146. doi:10.1093/asj/sjag140
BibTeX
@article{Melnikov2026,
author = {Melnikov, Dmitry V and Abdeeva, Elina I and Cotofana, Sebastian and Ivanov, Semyon I and Ratushniy, Nikolay A and Vorontsov, Alexander V and Gombolevskiy, Victor A},
title = {Noncontrast Magnetic Resonance Angiography vs Contrast-Enhanced Computed Tomography in Deep Inferior Epigastric Perforator Flap Planning: A 4-year Noninferiority Cohort Study},
journal = {Aesthetic Surgery Journal},
year = {2026},
volume = {46},
number = {10},
pages = {1137--1146},
doi = {10.1093/asj/sjag140}
}
EUVIMED